Alexander M Eggermont
Overview
Explore the profile of Alexander M Eggermont including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
4037
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ascierto P, Blank C, Eggermont A, Garbe C, Gershenwald J, Hamid O, et al.
J Transl Med
. 2023 Apr;
21(1):265.
PMID: 37072748
The Great Debate session at the 2022 Melanoma Bridge congress (December 1-3) featured counterpoint views from leading experts on five contemporary topics of debate in the management of melanoma. The...
2.
Ascierto P, Atkins M, Eggermont A, Gershenwald J, Grob J, Hamid O, et al.
J Transl Med
. 2021 Apr;
19(1):142.
PMID: 33827575
The Great Debate session at the 2020 Melanoma Bridge virtual congress (December 3rd-5th, Italy) featured counterpoint views from experts on five specific controversial issues in melanoma. The debates considered whether...
3.
Dammeijer F, van Gulijk M, Mulder E, Lukkes M, Klaase L, den Bosch T, et al.
Cancer Cell
. 2020 Oct;
38(5):685-700.e8.
PMID: 33007259
PD-1/PD-L1-checkpoint blockade therapy is generally thought to relieve tumor cell-mediated suppression in the tumor microenvironment but PD-L1 is also expressed on non-tumor macrophages and conventional dendritic cells (cDCs). Here we...
4.
Recondo G, Mezquita L, Facchinetti F, Planchard D, Gazzah A, Bigot L, et al.
Clin Cancer Res
. 2019 Oct;
26(1):242-255.
PMID: 31585938
Purpose: Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor with proven efficacy in patients with ALK-rearranged lung cancer previously treated with first- and second-generation ALK inhibitors. Beside...
5.
Jacquelot N, Yamazaki T, Roberti M, Duong C, Andrews M, Verlingue L, et al.
Cell Res
. 2019 Sep;
29(10):846-861.
PMID: 31481761
PD-1 blockade represents a major therapeutic avenue in anticancer immunotherapy. Delineating mechanisms of secondary resistance to this strategy is increasingly important. Here, we identified the deleterious role of signaling via...
6.
Amaria R, Menzies A, Burton E, Scolyer R, Tetzlaff M, Antdbacka R, et al.
Lancet Oncol
. 2019 Jul;
20(7):e378-e389.
PMID: 31267972
Advances in the treatment of metastatic melanoma have improved responses and survival. However, many patients continue to experience resistance or toxicity to treatment, highlighting a crucial need to identify biomarkers...
7.
Lebbe C, Garbe C, Stratigos A, Harwood C, Peris K, Del Marmol V, et al.
Eur J Cancer
. 2019 May;
114:117-127.
PMID: 31096150
Kaposi's sarcoma (KS) is a multifocal neoplasm of lymphatic endothelium-derived cells infected with human herpesvirus 8. Four clinical subtypes are distinguished: the classic, the endemic, the epidemic subtype in HIV...
8.
Cerezo M, Guemiri R, Druillennec S, Girault I, Malka-Mahieu H, Shen S, et al.
Nat Med
. 2018 Oct;
24(12):1877-1886.
PMID: 30374200
Preventing the immune escape of tumor cells by blocking inhibitory checkpoints, such as the interaction between programmed death ligand-1 (PD-L1) and programmed death-1 (PD-1) receptor, is a powerful anticancer approach....
9.
Jacquelot N, Zitvogel L, Eggermont A
Nat Commun
. 2018 Jul;
9(1):2922.
PMID: 30050125
No abstract available.
10.
Jacquelot N, Pitt J, Enot D, Roberti M, Duong C, Rusakiewicz S, et al.
Oncoimmunology
. 2017 Sep;
6(8):e1299303.
PMID: 28919986
Existing clinical, anatomopathological and molecular biomarkers fail to reliably predict the prognosis of cutaneous melanoma. Biomarkers for determining which patients receive adjuvant therapies are needed. The emergence of new technologies...